We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
An SI Board Since January 2011
Posts SubjectMarks Bans
0 1 0
Emcee:  StockDung Type:  Moderated



" will also disclose ny compensation. has been compensated Seventy-Five Thousand Dollars Cash by a third party (Apache Capital Group) for a 5 Day Marketing Program of GENM"

-----Original Message-----
From: StockMister <>
Sent: Tue, Jan 18, 2011 12:44 am
Subject: A new SM Play to start the week!

If you are experiencing Difficulties reading the profile on GENM below please use the following link:

Good Evening Traders,

I hope everyone had a Great Weekend!!! It's time to start the week with a brand new explosive play that could easily move during the next couple of days.. This one has just begun picking up some activity on Friday and it seems like we could really see some momentum during the next couple of days!! So without further interruptions I give you:

Genmed Holding Corporation (Public, OTC: GENM)

After this lengthy three-day weekend, we felt that it was the right time to bring you another company with the potential to revitalize the pharmaceutical industry. Generic Medicines have increasingly become alternatives to our everyday forms of medication. With more and more individuals opting for these alternatives, there is an increasing need for companies that focus their efforts on the distribution of such products to their respective retailers.

Genmed Holding Corporation (Public, OTC: GENM) focuses on the delivery of low-cost generic medicines to distribution chains in Europe and in other countries. An international U.S. and Holland-based company, they distribute generic medicines that generally become available when the originator patents expire. In accordance with governmental pressures and new insurance policies, these medicines are consistently used as alternatives to higher-priced originator pharmaceuticals.

Their goal is to contribute to this industry in a positive manner, and driven by ambition and passion for the business, they hope to provide accessibility to less expensive and safer FDA and EMEA approved generic medicines within Europe and around the world. Furthermore, they hope to benefit the investors that they interact with by providing them the returns that they deserve.

In comparison to their competitor's, they have several competitive advantages:

One of the biggest advantages that Genmed has is that it has already undertaken the time-consuming steps necessary to acquire distribution licenses in Romania, Holland, the U.K., U.S., Germany, and Ireland.

As a result of obtaining the licenses, Genmed can initiate new licenses in the rest of the world.

The ability to sell directly to the distributor and to eliminate the wholesaler from the distribution process offers the following benefits:

Lower Production Cost

Lower Distribution Cost

Faster Delivery

The Production facility already adheres to the strictest worldwide standards for generic pharmaceutical production.

Currently, they are evaluating supply agreements with worldwide distributors. While the company has initially focused on OTC products, it is currently developing its strategy to move into the prescription drug market.

For more information, visit the company's website at



Recent News

Genmed Enters European Generic Pharmaceuticals MarketPress Release
AMSTERDAM--(BUSINESS WIRE)-- Genmed Holding Corp. (OTCBB:GENM.ob -News ) is announcing its entry into the European generic drug market with the receipt of its first marketing and distribution license for paracetamol. Also known as acetaminophen, paracetamol is an over-the-counter drug used to treat mild to moderate pain from headaches, backaches, osteoarthritis, and to reduce fever.

Genmed first filed its application dossier for Paracetamol 500mg tablets with the Dutch Medicines Evaluation Board (MEB) in July 2008. The Dutch MEB is a member of the European Medicines Agency which evaluates and monitors the efficiency, risks, and quality of human medicinal products. The submission was done under mutual recognition for the following EU countries; Netherlands, Belgium, Luxembourg, Germany, France, Ireland, and the United Kingdom. The successful receipt of its license allows the Company to market and distribute its generic drugs within these countries. The Company recently received its official marketing authorization license and has been preparing for its first shipments of paracetamol, expected to take place within the first quarter of 2011.

Erwin Bouwens, Genmed's Chief Executive Officer said, "We are extremely excited about this development. Obtaining the license was a very long process and our perseverance has really paid off. We are looking forward now to begin shipping our first orders and moving on to obtaining additional licenses for generic drugs we feel have the appropriate market size and where we believe we can be competitive."

Genmed Seeks Piece of Multi-Billion Dollar Generic Drug Market
AMSTERDAM--(BUSINESS WIRE)-- Genmed Holding Corp. (OTCBB:GENM.ob -News ) released data today on the size and scope of the European Union's generic drug market. The countries of Western Europe represent a total market of over 365 million people and a combined GDP of over US$14.4 trillion. Major expansion of generic pharmaceutical sales is expected in EU countries such as Germany, France, the United Kingdom, Italy and Austria.

Governmental pressure and new insurance policies have increased the demand by general practitioners, specialists, and hospitals for generic medicines rather than the higher priced brand named pharmaceuticals. While innovator pharmaceutical revenues are expected to remain relatively flat in the course of 2011, generic active pharmaceutical ingredients (APIs) are predicted to experience growth at a much faster rate notes Senior Editor of Pharmaceutical Technology, Patricia Van Arnum.

In 2009, the global generics market generated approximately $84 billion in sales, according to US market data provider BCC Research, an increase of 7.7% from 2008 representing a compound annual growth rate of 11.9% for the five year period spanning 2004-2009.

According to Intercontinental Marketing Services Health (IMS Health), generic pharmaceuticals in the top eight markets, which include the United States, Canada, France, Germany, Italy, Spain, the United Kingdom and Japan, represent $62.6 billion dollars in revenue for 2009. Furthermore, generics now account for 72% of the total US pharmaceutical market volume alone, reaching an all-time high in 2009. Projections estimate that sales of generic products could exceed $100 billion worldwide in 2011.

The top ten global generic drug manufacturers and distributors account for approximately 66% of the market. Doug Long, vice-president, industry relations at IMS Health recently stated, "This means there are still many players out there that are pretty small and would be ripe for acquisitions or mergers...Everybody expects that there will be consolidation within the generic drugs industry..."

While not only growing faster in terms of revenues, generics are also saving government healthcare programs and the everyday consumer money. In the United States, generic medicines have saved the American health care system more than $734 billion dollars in the last decade while in the United Kingdom generic competition saves the National Health Service (NHS) £8.6 billion per annum.

Genmed Holding Corp. CEO, Reggie Bowens said, "We couldn't pick a better time to be entering the generics market with our first licensed product, paracetamol. With the ramp up of our sales teams in the European Union this quarter, we fully anticipate owning a piece of this enormous market."

As always, you should conduct your own research and take your own due diligence into account. This company, however, has the traits of a winner and in situations like these, we feel that our members should be the first to be notified!

As Always: Our Number 1 Priority is to educate and help our members trading, so, PLEASE ONLY Invest what you can afford to lose!! Trading Stocks is risky and we 100% feel that if you can't lose your ENTIRE investment and still continue your normal life than DON'T play the Stock Market.

Having that said, don't forget our rules: PLAY SMART. LIMIT YOUR LOSSES (10% STOP) AND CASH IN ON YOUR GAINS (10%+ WITH 5% TRAILING STOP)

P.S. Don't forget to sign-up for my mobile alerts by texting StockMister to 69302.

Thank you,
Rafael (StockMister)


*Never invest in a stock mentioned by unless you can afford to lose your entire investment.

Release of Liability: Through use of this website viewing or using you agree to hold, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may suffer. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Please be advised that is often compensated for issuing press releases, profiles or opinions concerning particular companies, its opinion is therefore biased and you should consider the factor when evaluating's statements regarding a company.'s officers and directors do not own any shares of the mentioned company(s). When receives free or restricted trading shares as a compensation for a profiled company, may sell part or all of such shares during the period in which is performing such services. will disclose how many and what type of shares we have been compensated if we do receive shares or buy shares of a profiled company. will also disclose any compensation. has been compensated Seventy-Five Thousand Dollars Cash by a third party (Apache Capital Group) for a 5 Day Marketing Program of GENM. This compensation/expected compensation, expired or not, is a major conflict of interest in our ability to be unbiased. Therefore, this newsletter should be read as a commercial advertisement only. The third party, company, or their affiliates may wish to liquidate shares, which has the potential to hurt share prices . Our emails may contain forword looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. encourages readers and investors to supplement the information in this report with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies., nor any of its affiliates are not registered investment advisors or a broker dealers. Please read our FULL Disclaimer at

P.O. Box 50123, New York City, NY 01012, USA

To unsubscribe or change subscriber options visit:
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
 Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):